Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.40 |
| ▸ | MAOA | P21397 | 5/20 | 0.40 |
| ▸ | F10 | P00742 | 7/20 | 0.39 |
| ▸ | CALML3 | P27482 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SDHA | P31040 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13367839 | 0.96 | MAOA (0.40) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL10151842 | 0.91 | MAOB (0.51) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL10152103 | 0.91 | F10 (0.42) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL10152129 | 0.88 | MAOB (0.41) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL10152799 | 0.88 | CYP3A4 (0.38) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL10152104 | 0.88 | MAOA (0.48) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL10152121 | 0.87 | F10 (0.43) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL15827775 | 0.86 | MAOA (0.41) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL10152668 | 0.86 | MAOA (0.42) | MAOBMAOAF10CALML3LMNA | |
| SCHEMBL10152131 | 0.85 | MAOB (0.50) | MAOBMAOAF10CALML3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208997-A1 | NOVEL COMPOUND HAVING HETEROCYCLIC RING | SUZUKI HIDEYUKI (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8148362-B2 | Compound having heterocyclic ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148362-B2 | Compound having heterocyclic ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-2181994-A1 | Antimicrobial compounds | Research Foundation Itsuu Laboratory (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-12-03 | — | — | US | disclosed |
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2009012-A1 | NOVEL COMPOUND HAVING HETEROCYCLIC RING | Research Foundation Itsuu Laboratory (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | NR0B2, NR2C2, NR0B1 | MAOB 2611/4885MAOA 2965/4885F10 3469/4885 |
| US-20120208997-A1 | NOVEL COMPOUND HAVING HETEROCYCLIC RING | OXA1L, MRPL21, TOP1 | MAOB 1404/4885MAOA 1563/4885F10 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.